Volume | 348,272 |
|
|||||
News | - | ||||||
Day High | 108.235 | Low High |
|||||
Day Low | 102.74 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
ICU Medical Inc | ICUI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
103.05 | 102.74 | 108.235 | 107.32 | 102.89 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
9,270 | 348,272 | $ 106.96 | $ 37,252,911 | - | 78.28 - 212.43 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:26:21 | 44 | $ 107.25 | USD |
ICU Medical Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.59B | 24.14M | - | 2.28B | -29.66M | -1.23 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ICU Medical News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ICUI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 97.32 | 108.235 | 95.33 | 99.69 | 232,086 | 10.00 | 10.28% |
1 Month | 114.39 | 114.39 | 95.33 | 102.22 | 280,239 | -7.07 | -6.18% |
3 Months | 95.20 | 123.46 | 86.80 | 99.91 | 263,764 | 12.12 | 12.73% |
6 Months | 116.84 | 123.46 | 78.28 | 95.52 | 319,081 | -9.52 | -8.15% |
1 Year | 156.46 | 212.43 | 78.28 | 121.83 | 254,369 | -49.14 | -31.41% |
3 Years | 209.43 | 282.00 | 78.28 | 164.43 | 202,218 | -102.11 | -48.76% |
5 Years | 235.20 | 282.00 | 78.28 | 175.79 | 188,995 | -127.88 | -54.37% |
ICU Medical Description
ICU Medical is a California-based, pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. After ICU's acquisition of Hospira Infusion Systems from Pfizer in 2017, it became one of the largest players in this concentrated industry, holding top-tier positions in its major reporting segments: infusion consumables (37% of 2020 revenue), IV solutions (31%), infusion systems (28%), and critical care (4%). The combined entity remains primarily U.S. focused, generating over 70% of its sales domestically. |